SCHEMBL13381099

SCHEMBL13381099

CCC1COC2(CCCCC2)O1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.59
CTDSP1 Q9GZU7 1/20 0.59
GAA P10253 1/20 0.54
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
HTR1A P08908 5/20 0.43
ADRA1D P25100 4/20 0.43
ADRA1B P35368 4/20 0.43
ADRA1A P35348 3/20 0.42
ALDH1A1 P00352 2/20 0.42
BRD4 O60885 1/20 0.40
ABL1 P00519 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
RIN1 Q13671 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.38
CHRM2 P08172 3/20 0.31
CHRM3 P20309 3/20 0.31
CHRM4 P08173 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18885118 1.00 PABPC1 (0.59) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL13381093 0.98 PABPC1 (0.56) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL13381097 0.93 PABPC1 (0.51) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL12943471 0.86 PABPC1 (0.54) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL13381193 0.83 PABPC1 (0.51) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL11175752 0.83 PABPC1 (0.51) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL20624944 0.83 PABPC1 (0.51) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL11177497 0.83 PABPC1 (0.51) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL10000249 0.81 PABPC1 (0.50) PABPC1CTDSP1GAATMEM97SIGMAR1
SCHEMBL8192982 0.81 PABPC1 (0.53) PABPC1CTDSP1GAATMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435432-B3 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE IRELAND UNLIMITED CO (BM) 2023-10-25 EP disclosed
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
WO-2019065283-A1 PYRIDAZINONE COMPOUND OR SALT THEREOF AND HERBICIDE CONTAINING SAME 石原産業株式会社 2019-04-04 WO disclosed
US-9527809-B2 Compound, actinic ray-sensitive or radiation-sensitive resin composition, resist film, and pattern formation method, and method for manufacturing electronic device using same, and electronic device FUJIFILM CORPORATION (JP) 2016-12-27 US disclosed
US-20160024005-A1 COMPOUND, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, AND PATTERN FORMATION METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE USING SAME, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2016-01-28 US disclosed
WO-2013125733-A1 PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE USING THE SAME AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2013-08-29 WO disclosed
US-20100081693-A1 THIADIAZOLE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-01 US disclosed
US-20100081693-A1 THIADIAZOLE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-01 US disclosed
US-20080204608-A1 Liquid Crystal Element, Optical Path Deflecting Element, and Image Displaying Apparatus RICOH COMPANY, LTD. (JP) 2008-08-28 US disclosed
US-20070129576-A1 Process for preparing fluorine-containing norbornene derivative DAIKIN INDUSTRIES, LTD. 2007-06-07 US disclosed
US-7186773-B2 Process for preparing fluorine-containing norbornene derivative DAIKIN INDUSTRIES, LTD. (JP) 2007-03-06 US disclosed
US-7186773-B2 Process for preparing fluorine-containing norbornene derivative DAIKIN INDUSTRIES, LTD. (JP) 2007-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024005-A1 COMPOUND, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, AND PATTERN FORMATION METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE USING SAME, AND ELECTRONIC DEVICE RER1, RAD51, TERB1 PABPC1 2090/4885CTDSP1 1241/4885GAA 2568/4885
US-20070129576-A1 Process for preparing fluorine-containing norbornene derivative ADH1A, FLNA, FFAR2 PABPC1 3948/4885CTDSP1 852/4885GAA 4336/4885
US-20100081693-A1 THIADIAZOLE COMPOUND AND USE THEREOF NR2C2, NR4A3, NR0B2 PABPC1 4258/4885CTDSP1 2879/4885GAA 4884/4885
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections HCCS, HAVCR2, NR1H4 PABPC1 1822/4885CTDSP1 157/4885GAA 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.